Darifenacin

Chemical formula: C₂₈H₃₀N₂O₂  Molecular mass: 426.55 g/mol  PubChem compound: 444031

Active ingredient description

Darifenacin is a selective muscarinic M3 receptor antagonist (M3 SRA) in vitro. The M3 receptor is the major subtype that controls urinary bladder muscle contraction. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
G04BD10 Darifenacin G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics
Discover more medicines within G04BD10

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
EMSELEX Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC
ENABLEX Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 133099-04-4
DrugBank Drug: DB00496
KEGG Drug: D01699
PubChem Compound: 444031
RxNorm Ingredient: 136198
SNOMED-CT Concept: 416140008
Darifenacin (substance)
UNII Identifier: APG9819VLM
DARIFENACIN

Medicines

Darifenacin is an active ingredient of these brands:

United States (US)

  • ENABLEX as DARIFENACIN HYDROBROMIDE

Austria (AT)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Brazil (BR)

  • ENABLEX as DARIFENACIN HYDROBROMIDE
  • FENAZIC as DARIFENACIN HYDROBROMIDE

Canada (CA)

  • ENABLEX as DARIFENACIN HYDROBROMIDE

Croatia (HR)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Cyprus (CY)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Ecuador (EC)

Estonia (EE)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Finland (FI)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Germany (DE)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Hong Kong (HK)

  • ENABLEX as DARIFENACIN HYDROBROMIDE

Ireland (IE)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Lithuania (LT)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Mexico (MX)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Netherlands (NL)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

New Zealand (NZ)

  • ENABLEX as DARIFENACIN HYDROBROMIDE

Poland (PL)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Romania (RO)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

South Africa (ZA)

  • ENABLEX as DARIFENACIN HYDROBROMIDE
  • FLODEN as DARIFENACIN HYDROBROMIDE
  • OABMAK as DARIFENACIN HYDROBROMIDE
  • TANZAFLO as DARIFENACIN HYDROBROMIDE

Turkey (TR)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

United Kingdom (UK)

  • EMSELEX as DARIFENACIN HYDROBROMIDE

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.